# SPYRE THERAPEUTICS, INC. (SYRE) · Edgar & Edgarette company card

> Spyre Therapeutics (SYRE) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 92.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1636282 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SYRE) · [JSON](https://www.pops4.com/boards/company/SYRE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$169M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $86M |
| Long-term debt | — |
| Total assets | $778M |
| Total equity | $715M |
| Equity ÷ assets | 92.0% |
| Return on equity | -21.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 11.54 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$169.3M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 92.0% of assets, return on equity -21.7%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-05-29 ([filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/0001636282-26-000132-index.htm)
- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000131/0001636282-26-000131-index.htm)
- 8-K · filed 2026-10-07 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/0001628280-26-065291-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/0001636282-26-000113-index.htm)
- 8-K · filed 2026-08-25 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/0001636282-26-000105-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/0001636282-26-000098-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001636282.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1636282

## Cite

POPS4, Edgar & Edgarette: SPYRE THERAPEUTICS, INC. (SYRE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/SYRE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.